DB04893ExperimentalSmall molecule
AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004. As of February... As of February 2007 the development of AZD3409 had been discontinued.
- Mechanism
- Curator reviewed
In preclinical studies, AZD3409 achieves up to 90% inhibition of FTase in tumors at well tolerated doses. In enzyme studies AZD3409 is also known to inhibit GGTase-1.
- Primary indication
- For the treatment of solid tumors.Curator reviewed
- Code names
- AZD3409
Resolves to
Compound
Targets
What you can answer from here — as of April 02, 2025
2Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with AZD3409, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account